H. Lee Moffitt Cancer Center and Research Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, H. Lee Moffitt Cancer Center and Research Institute sits in the top decile of US sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count).
H. Lee Moffitt Cancer Center and Research Institute: 502 sponsored US clinical trials, 82 recruiting.
H. Lee Moffitt Cancer Center and Research Institute sponsors 502 registered US clinical trials on ClinicalTrials.gov, 82 of them currently recruiting, and 280 completed. 5 of these trials are in Phase 3-4 (later-stage) and 335 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
H. Lee Moffitt Cancer Center and Research Institute ranks in the top decile of sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
280 of 344 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
502 total, page 7 of 11
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
NCT02115542
Navigator Guided e-Psychoeducational Intervention
NCT02186444
Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
NCT02138383
Latinos CARES (Colorectal Cancer Awareness, Research, Education and Screening)
NCT03078361
HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy
NCT02061423
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
NCT01841021
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis
NCT01927120
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
NCT02032810
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
NCT01999985
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
NCT01859026
Physical Activity for Advanced Stage Cancer Patients
NCT02015936
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
NCT01886287
Yoga for Aromatase Inhibitor-associated Joint Pain
NCT01951976
Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
NCT01846429
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)
NCT01842646
Randomized Controlled Trial of Endoscopic Dilation: Triamcinolone Injection
NCT01873573
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)
NCT01822691
Feasibility Study of Ultrasound Elastography Detecting Prostate Cancer
NCT03077126
Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
NCT01713400
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
NCT01702064
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
NCT01776723
Study of Gardasil in Mid-Adult Males (MAM)
NCT01432574
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
NCT01795586
Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant
NCT01852591
GTX-RT in Borderline Resectable Pancreatic Cancer
NCT01754623
Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study
NCT01760499
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
NCT01683149
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
NCT01680965
Pilot Study of Regional Lung Ventilation
NCT03077113
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
NCT01701674
Metformin in Children With Relapsed or Refractory Solid Tumors
NCT01528046
Preparedness Study - HPV Vaccine
NCT01489527
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
NCT01659151
Genetic Counseling for Breast Cancer Survivors (GC for BC)
NCT02451735
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
NCT01657591
Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma
NCT01606345
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
NCT01531205
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
NCT01581307
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
NCT01496976
Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer
NCT01433172
Stress Management Training for Latinas Receiving Chemotherapy
NCT01599520
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma
NCT01496807
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT01497496
Smoking Relapse-Prevention Intervention for Cancer Patients
NCT01630161
Increasing Access to Colorectal Cancer Testing (IACCT) for Blacks
NCT03078348
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
NCT01373294
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
NCT01432600
A Study of Axitinib in Advanced Carcinoid Tumors
NCT01435122
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC
NCT01437605
Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects
NCT01450046
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 167 |
| Phase 2 | 168 |
| Phase 3 | 3 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the H. Lee Moffitt Cancer Center and Research Institute pipeline
82 recruiting of 502 indexed (16% open); 280 completed (56%).
Phase mix: 5 late (III/IV) vs 335 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
H. Lee Moffitt Cancer Center and Research Institute: open-pipeline peers nationwide
Peers matched on 502 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
H. Lee Moffitt Cancer Center and Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 502 trials (± recruiting share)
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Boehringer Ingelheim · 515 trials · 8% recruiting
Sponsors near 16% open enrollment (± trial volume)
- Case Western Reserve University · 16% recruiting · 141 trials
- Drexel University · 16% recruiting · 92 trials
- Atlantic Health System · 16% recruiting · 43 trials
- BioMarin Pharmaceutical · 16% recruiting · 80 trials
Related
What to do with this H. Lee Moffitt Cancer Center and Research Institute page
502 registered trials is a research-attention snapshot, not an endorsement of H. Lee Moffitt Cancer Center and Research Institute or any single study.
- 82 of H. Lee Moffitt Cancer Center and Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition H. Lee Moffitt Cancer Center and Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. H. Lee Moffitt Cancer Center and Research Institute pipeline card: 502 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.